Validation of the FIGO Nutrition Checklist in Pregnant Women

计划入组 120 人 · 首次发布于 2025 年 9 月 19 日

Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer

计划入组 40 人 · 首次发布于 2024 年 3 月 1 日

Neoadjuvant Chemotherapy + Surgery Versus Surgery in FIGO IB2 and IIA2 Cervical Cancer

计划入组 700 人 · 首次发布于 2015 年 12 月 14 日

Figopitant

C₂₇H₃₁F₆N₃O

Fig

Ad26.Filo

Xigo Health, LLC

United States

COMPLEJO HOSPITALARIO UNIVERSITARIO DE VIGO

Spain

Pembrolizumab Plus Chemotherapy Demonstrates DFS Benefit in dMMR Endometrial Cancer Subgroup

PD-L1 Expression Correlates with HRD Status and Predicts Survival in High-Grade Serous Ovarian Cancer

TRUST Trial Shows Primary Surgery Improves Progression-Free Survival in Advanced Ovarian Cancer Despite Missing Overall Survival Endpoint